[
  {
    "token_count": 250,
    "subprompt": "If you have been caught in the legal trap of a domestic violence case then it can snatch your employment, your home and any chance of living a normal life in the future. So contact an efficient domestic violence lawyer Colorado immediately and get the best solution for your problems. For further information please visit out website\n\nNeon Therapeutics Files for $100 Million IPO for Immuno-Oncology Pipeline\n\n\n\nNeon Therapeutics (Proposed Nasdaq: NTGN) has filed for a $100 million initial public offering to fund clinical development of its neoantigen program. Neoantigens result from mutations occurring during tumor growth, are recognized as foreign and differ from native antigens to which the immune system is tolerant. The presence of neoantigens in cancer cells and their absence in normal cells makes them compelling, untapped targets for cancer therapy.\n\n\n\nThe company launched in 2015 with a $55 million Series A investment led by Third Rock Ventures with participation from Clal Biotechnology Industries and Access Industries. The $106 million Series B round in 2017 was led by Partner Fund Management and joined by Third Rock and Access, along with new investors Fidelity, Wellington, Inbio Ventures, Nextech Invest, Pharmstandard",
    "output": ", and Vyome Biosciences.\n\n\n\nNeon is developing a portfolio of proprietary cancer immunotherapy products that target neoantigens. The company's lead product NEO-201 is a neoantigen vaccine that is designed to prevent and treat cancer by inducing cell-mediated immunity and suppressing the tumor immune profile.\n\n\n\nNeon's portfolio of neoantigen products includes a Phase II clinical trial with NEO-201 in patients with melanoma. A Phase Ib trial in patients with prostate cancer was initiated in June 2018.\n\n\n\n\"The success of our neoantigen program is expected to be driven by NEO-201, which is the first and only neoantigen vaccine in clinical development and is currently being evaluated in patients with melanoma, prostate, and lung cancers,\" said Neon's CEO, Amarjit Sahota. \"We believe that our lead neoantigen product, NEO-201, has the potential to significantly reduce the morbidity and mortality associated with cancer.\"\n\n\n\nNeon's portfolio of neoantigen products includes:\n\n\n\n\u2022 NEO-201, an autologous vaccine to prevent and treat cancer by inducing cell-mediated immunity and suppressing the tumor immune profile\n\n\u2022 NEO-201-01, a Phase II clinical trial with",
    "similarity_score": 0.7699090242385864
  },
  {
    "token_count": 375,
    "subprompt": "If you have been caught in the legal trap of a domestic violence case then it can snatch your employment, your home and any chance of living a normal life in the future. So contact an efficient domestic violence lawyer Colorado immediately and get the best solution for your problems. For further information please visit out website\n\nNeon Therapeutics Files for $100 Million IPO for Immuno-Oncology Pipeline\n\n\n\nNeon Therapeutics (Proposed Nasdaq: NTGN) has filed for a $100 million initial public offering to fund clinical development of its neoantigen program. Neoantigens result from mutations occurring during tumor growth, are recognized as foreign and differ from native antigens to which the immune system is tolerant. The presence of neoantigens in cancer cells and their absence in normal cells makes them compelling, untapped targets for cancer therapy.\n\n\n\nThe company launched in 2015 with a $55 million Series A investment led by Third Rock Ventures with participation from Clal Biotechnology Industries and Access Industries. The $106 million Series B round in 2017 was led by Partner Fund Management and joined by Third Rock and Access, along with new investors Fidelity, Wellington, Inbio Ventures, Nextech Invest, Pharmstandard International, Arrowmark Partners, Hillhouse Capital and Casdin Capital. The IPO will be led by Morgan Stanley, BofA Merrill Lynch and Mizuho Securities.\n\n\n\nNeon is developing a pipeline of personalized neoantigen vaccines and autologous T cell therapies, with an initial focus on melanoma, non-small cell lung cancer (NSCLC) and bladder cancer. The company has collaboration and licensing agreements in place with Vedantra Pharmaceuticals, Apexigen, CRISPR Therapeutics, Bristol-Myers Squibb, Merck, the Netherlands Cancer Institute, the Broad Institute, Dana-Far",
    "output": "ber Cancer Institute and MD Anderson Cancer Center, Novartis, and the National Cancer Institute.\n\n\n\n\u201cWe are pleased to report that Neoantigen development has progressed well with a number of early-stage clinical candidates entering Phase 1 and Phase 2 clinical trials,\u201d said Neon President and CEO Michael M. Kastanis. \u201cWe look forward to continuing to make progress in developing this important class of immunotherapies, which could have a meaningful impact on the treatment of cancer.\u201d\n\n\n\nTo learn more about the company, please visit: http://www.neontherapeutics.com\n\n\n\nIf you have been caught in the legal",
    "similarity_score": 0.7315315008163452
  },
  {
    "token_count": 500,
    "subprompt": "If you have been caught in the legal trap of a domestic violence case then it can snatch your employment, your home and any chance of living a normal life in the future. So contact an efficient domestic violence lawyer Colorado immediately and get the best solution for your problems. For further information please visit out website\n\nNeon Therapeutics Files for $100 Million IPO for Immuno-Oncology Pipeline\n\n\n\nNeon Therapeutics (Proposed Nasdaq: NTGN) has filed for a $100 million initial public offering to fund clinical development of its neoantigen program. Neoantigens result from mutations occurring during tumor growth, are recognized as foreign and differ from native antigens to which the immune system is tolerant. The presence of neoantigens in cancer cells and their absence in normal cells makes them compelling, untapped targets for cancer therapy.\n\n\n\nThe company launched in 2015 with a $55 million Series A investment led by Third Rock Ventures with participation from Clal Biotechnology Industries and Access Industries. The $106 million Series B round in 2017 was led by Partner Fund Management and joined by Third Rock and Access, along with new investors Fidelity, Wellington, Inbio Ventures, Nextech Invest, Pharmstandard International, Arrowmark Partners, Hillhouse Capital and Casdin Capital. The IPO will be led by Morgan Stanley, BofA Merrill Lynch and Mizuho Securities.\n\n\n\nNeon is developing a pipeline of personalized neoantigen vaccines and autologous T cell therapies, with an initial focus on melanoma, non-small cell lung cancer (NSCLC) and bladder cancer. The company has collaboration and licensing agreements in place with Vedantra Pharmaceuticals, Apexigen, CRISPR Therapeutics, Bristol-Myers Squibb, Merck, the Netherlands Cancer Institute, the Broad Institute, Dana-Farber Cancer Institute and Massachusetts General Hospital.\n\n\n\nSource: Neon Therapeutics\n\n\n\nIn May 2018, Neon announced that it had treated its first patient in a Phase I clinical trial evaluating its proprietary personal neoantigen vaccine, NEO-PV-01, in combination with Merck\u2019s Keytruda (anti PD-1 therapy) and a chemotherapy regimen of pemetrexed and carboplatin in patients with untreated or advanced metastatic nonsquamous NSCLC. The trial is being conducted in collaboration with Merck. In addition to evaluating the safety, tolerability and preliminary efficacy of the combination therapy,",
    "output": " the trial will also evaluate",
    "similarity_score": 0.6548653841018677
  }
]